Regarding the safety of SGLT-2 inhibitors, RCTs have shown that the use of SGLT-2 inhibitors in diabetic and non-diabetic patients with CKD is generally safe [1,2,3,4]. This evidence concerns the gene SLC5A2 and chronic kidney disease.